Triple-Negative Breast Cancer (TNBC) Recruiting Phase 3 Trials for Atezolizumab (DB11595)

Also known as: Triple-negative Breast Cancer

IndicationStatusPhase
DBCOND0067309 (Triple-Negative Breast Cancer (TNBC))Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03125902A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)Treatment